Summary Background Infections with SARS-CoV-2 continue to cause significant morbidity
and mortality. Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic …

There is growing evidence that thrombotic and inflammatory pathways contribute to the
severity of COVID-19. Common medications such as aspirin, that mitigate these pathways …

Background Aspirin is widely used as a cardioprotective agent due to its antiplatelet and anti-
inflammatory properties. The literature has assessed and evaluated its role in hospitalized …

Rationales and uncertainties for aspirin use in COVID-19: a narrative review - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …

Introduction During COVID-19 pandemic, the use of several drugs has represented the
worldwide clinical practice. However, though the current increase of knowledge about the …

OBJECTIVES: Since the onset of the coronavirus disease 2019 pandemic, immune
modulators have been considered front-line candidates for the management of patients …

Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …

Background The COVID-19 pandemic remains an immediate and present concern, yet as of
now there is still no approved therapeutic available for the treatment of COVID-19. This study …

Hypercoagulability and thrombosis caused by coronavirus disease 2019 (COVID‐19) are
related to the higher mortality rate. Because of limited data on the antiplatelet effect, we …

Since the beginning of the Covid-19 pandemic, the scientific community has explored
determinants of Covid 19 disease severity. However, the majority of studies are based on in …